Top Markets
Coin of the day
Acticor Biotech SAS Acticor Biotech SAS

Acticor Biotech SAS

ALACT
株式のランク #37014
Acticor Biotech SAS is a clinical-stage biotechnology firm focused on creating... Acticor Biotech SAS is a clinical-stage biotechnology firm focused on creating therapies for the acute phase of thrombotic conditions. The company's lead compound, glenzocimab, is a humanized monoclonal antibody fragment specifically designed to target a particular platelet glycoprotein. Currently, Acticor Biotech is advancing two clinical programs, both in Phase II/III, for the registration of treatments for ischemic stroke. Additionally, it is conducting two other Phase II trials concerning significant cardiovascular emergencies, with anticipated clinical data expected from both its ischemic stroke research and studies related to COVID-19 respiratory distress syndrome. Established in 2013, the company operates from its headquarters in Paris, France.
株価
$0.25974701
最終同期: 2025-01-06
時価総額
$2.04M
変化(1日)
0.74%
変化(1年)
0.00%
FR
取引 Acticor Biotech SAS (ALACT)

カテゴリー

Acticor Biotech SAS(ALACT)のP/B比率
September 2026 時点のP/B比率 TTM: -0.57
Acticor Biotech SAS の最新の財務報告および株価によると、現在のP/B比率(TTM)は -0.57 です。2022 年末時点でのP/B比率は -33.19 でした。
Acticor Biotech SAS の P/B 比率の履歴(2010 ~ 2026)
各年末時点のP/B比率
P/B比率 変化
2026 (TTM) -0.57 -91.38%
2023 -6.59 -80.15%
2022 -33.19 -1,126.36%
2021 3.23 -87.62%
2020 26.12 538.96%
2019 4.09 17.85%
2018 3.47 -160.01%
2017 -5.78 -511.84%
2016 1.40 2.83%
2015 1.37 7.92%
2014 1.26 5.23%
2013 1.20 -8.34%
2012 1.31 -12.44%
2011 1.50 -91.22%
2010 17.05 0.00%
同業他社のP/B比率
企業 P/B比率 P/B比率の差
6.5144 -1,247.10%
US
7.3983 -1,402.75%
NL
3.9974 -803.89%
AU
8.5918 -1,612.91%
US
- -
CH